0001847903-24-000011.txt : 20240102
0001847903-24-000011.hdr.sgml : 20240102
20240102194107
ACCESSION NUMBER: 0001847903-24-000011
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231231
FILED AS OF DATE: 20240102
DATE AS OF CHANGE: 20240102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GRAINGER DAVID J
CENTRAL INDEX KEY: 0001887115
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40445
FILM NUMBER: 24504042
MAIL ADDRESS:
STREET 1: C/O CENTESSA PHARMACEUTICALS PLC
STREET 2: 3RD FL., 1 ASHLEY RD, ALTRINCHAM
CITY: CHESHIRE
STATE: X0
ZIP: WA14 2DT
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Centessa Pharmaceuticals plc
CENTRAL INDEX KEY: 0001847903
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3RD FLOOR
STREET 2: 1 ASHLEY ROAD
CITY: ALTRINCHAM, CHESHIRE
STATE: X0
ZIP: WA14 2DT
BUSINESS PHONE: 44 7391 789784
MAIL ADDRESS:
STREET 1: 3RD FLOOR
STREET 2: 1 ASHLEY ROAD
CITY: ALTRINCHAM, CHESHIRE
STATE: X0
ZIP: WA14 2DT
FORMER COMPANY:
FORMER CONFORMED NAME: Centessa Pharmaceuticals Ltd
DATE OF NAME CHANGE: 20210224
4
1
wk-form4_1704242457.xml
FORM 4
X0508
4
2023-12-31
1
0001847903
Centessa Pharmaceuticals plc
CNTA
0001887115
GRAINGER DAVID J
C/O CENTESSA PHARMACEUTICALS PLC
3RD FL., 1 ASHLEY RD, ALTRINCHAM
CHESHIRE
X0
WA14 2DT
UNITED KINGDOM
0
1
0
0
Chief Innovation Officer
0
Ordinary Shares
2023-12-31
4
F
0
4700
7.96
D
962790
D
Ordinary Shares
27500
I
See footnote
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
/s/ Gregory Weinhoff, attorney-in-fact
2024-01-02